TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01510171

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prasugrel
Description: 25 patients with STEMI undergoing PPCI with bivalirudin (GP IIb/IIIa not allowed ) will be enrolled to receive 60 mg Prasugrel loading dose before PPCI. The loading dose will be performed as soon as possible in the Emergency Room or in the Cath Lab. In the case of vomit in the 2 hours after drug loading dose a new loading dose will be administered.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ticagrelor
Description: 25 patients with STEMI undergoing PPCI with bivalirudin (GP IIb/IIIa not allowed ) will be enrolled to receive 180 Ticagrelor loading dose before PPCI. The loading dose will be performed as soon as possible in the Emergency Room or in the Cath Lab. In the case of vomit in the 2 hours after drug loading dose a new loading dose will be administered.
Study: NCT03668990

Intervention type: OTHER
Group type: OTHER
Intervention: IMUs (Xsens, MVN Studio)
Description: It is a full-body human measurement system based on inertial sensors, biomechanical models and sensor fusion algorithms applied in neurological patients for measuring upper limb movements.

Intervention type: OTHER
Group type: OTHER
Intervention: IMUs (Xsens, MVN Studio)
Description: It is a full-body human measurement system based on inertial sensors, biomechanical models and sensor fusion algorithms applied in neurological patients for measuring upper limb movements.

Intervention type: OTHER
Group type: OTHER
Intervention: IMUs (Xsens, MVN Studio)
Description: It is a full-body human measurement system based on inertial sensors, biomechanical models and sensor fusion algorithms applied in neurological patients for measuring upper limb movements.
Study: NCT03500588

Intervention type: DIAGNOSTIC_TEST
Intervention: PCR
Description: Polymerase chain reaction was used to diagnose gene polymorphism.

Intervention type: DIAGNOSTIC_TEST
Intervention: PCR
Description: Polymerase chain reaction was used to diagnose gene polymorphism.

Intervention type: DEVICE
Intervention: Doppler ultrasound
Description: Doppler ultrasound was used to assess the pulsatility index of the umbilical artery .
Study: NCT04023123

Intervention type: OTHER
Intervention: Ophthalmic imaging
Description: Optical coherence tomography Topography Ocular Response Analyzer Optical Biometry Slit lamp photos

Intervention type: OTHER
Intervention: Ophthalmic imaging
Description: Optical coherence tomography Topography Ocular Response Analyzer Optical Biometry Slit lamp photos

Intervention type: OTHER
Intervention: Ophthalmic imaging
Description: Optical coherence tomography Topography Ocular Response Analyzer Optical Biometry Slit lamp photos
Study: NCT03919227

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: empty bladder before inserting UAS
Description: In group 1, investigator empty the bladder of urine with a catheter before inserting UAS, so that we can see if the empty bladder is easier for inserting UAS.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: do not interfere with the filling degree of bladder
Description: In group 2, investigator does not interfere with the filling degree of bladder before inserting UAS, so that we can see if the filling degree of bladder has impact on the insertion of UAS.
Study: NCT01300351

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fulvestrant
Description: Fulvestrant was supplied as a castor oil based solution in clear neutral glass pre-filled syringes. Each syringe will contain 250 mg of fulvestrant in 5 ml.
Study: NCT04317079

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Hydroxytyrosol
Description: Administration of hydroxytyrosol in doses 15mg and 5 mg compared to placebo for 6 months

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Diet
Description: Consultation by a dietitian was offered to all participants
Study: NCT01300351

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Fulvestrant was supplied as a castor oil based solution in clear neutral glass pre-filled syringes. Each syringe will contain 250 mg of fulvestrant in 5 ml.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Matching placebo was supplied as a castor oil based solution in clear neutral glass prefilled syringes. Each syringe will contain 5 ml.
Study: NCT02230683

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IDN-6556
Description: 25 mg BID
Study: NCT04317079

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Diet
Description: Consultation by a dietitian was offered to all participants

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Diet
Description: Consultation by a dietitian was offered to all participants
Study: NCT02230683

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IDN-6556
Description: 25 mg BID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IDN-6556
Description: 25 mg BID
Study: NCT02345356

Intervention type: GENETIC
Intervention: Genotype-guided
Description: Individual warfarin dose adjustments by using a pharmacogenetically driven algorithm

Intervention type: OTHER
Intervention: Standard-of-Care
Description: Individual warfarin dose adjustments by using a clinically driven algorithm (standard care)
Study: NCT02042534

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Description: Rivaroxaban group receive oral rivaroxaban 10 mg once daily for 5 consecutive days, followed by 20 mg or 15 mg in patients with a calculated creatinine clearance of 30-49 ml/min.~The dosage of rivaroxaban is leveraged from results of ROCKET-AF trial, where 20 mg of rivaroxaban was shown to offer balanced efficacy and safety.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Warfarin
Description: To harmonize the warfarin regimen across the sites, fixed algorithm was used in dose calculation, both loading and maintenance, and age, sex, ethnicity, race, weight, height, smoking history, presence of liver disease, indication, baseline INR, target INR and concomitant medication were considered as cofactors (http://www.warfarindosing.org/Source/InitialDose.aspx). Investigators will manage anticoagulation with warfarin per routine clinical care.
Study: NCT01976858

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEX168
Description: A injection administered subcutaneously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEX168
Description: A injection administered subcutaneously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEX168
Description: A injection administered subcutaneously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEX168
Description: A injection administered subcutaneously

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PEX168
Description: A injection administered subcutaneously
Study: NCT01009346

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RAD001
Description: Dose Level -1 2.5mg/day~Dose Level 1 5mg/day\*~Dose Level 2 10mg/day~MTD RAD001

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: 250mg/m2/week

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 40mg/m2 Day 1, 8 every 28 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin will be administered on Day1 and Day 8 of each 28 day cycle to a target AUC of 3 over 30 minutes. Carboplatin will be dosed using the Calvert formula:~Total dose (mg) = (target AUC) x (glomerular filtration rate + 25) Creatinine clearance will be used to estimate the GFR. The Cockgroft-Gault formula will be used to estimate the creatinine clearance.
Study: NCT00947414

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Extracorporeal shockwave therapy
Description: Extracorporeal shockwave therapy with focussed shock waves (2000 impulses, 0,25mJ/mm2) plus daily gluteal exercises

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham extracorporeal shock wave plus gluteal strength exercise
Description: Sham extracorporeal shock wave plus gluteal strength exercise
Study: NCT04790487

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CPM
Description: one spray dose (\~100 µL of the solution containing 1.25 mg CPM) per nostril twice a day

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline
Study: NCT02846246

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Person-centred and health-promoting home care service
Description: Firstly, staff will take part in an educational program on the content and operationalization of the central theoretical components person-centeredness and health exploratory conversation. Secondly, staff will participate in supervised skill training in how to accomplish person-centered and health exploratory conversation. Thirdly, the staff will have a person-centred and health exploratory conversation with purpose to evaluate the extent to which current home care service practice meet the older person´s need and maintain or make rearrangement in provided care to maximise older people's health. Finally, staff will participate in clinical supervisory sessions with an aim to support and facilitate ongoing operationalization phase.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Care as usual
Description: The control group will be offered a lecture about dementia based on staff wishes and a usual care paradigm will guide the control units, i.e. a continuation with practice as usual. Control units will receive the intervention protocol and study results at the end of the study.
Study: NCT04109846

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Non-euploid embryo transfer
Description: Other than choice of embryo for transfer, all other medical interventions will be at discretion of treating provider

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Euploid Transfer
Description: Standard of Care Protocol
Study: NCT02022241

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: triptorelin
Description: 0.2 mg, ih, at night and 0.2 mg, ih, 12 hours later when at least one of the following criteria was reached: (i) serum E2 ≥3500 pg/ml, (ii) ≥18 follicles measuring ≥11 mm.
Study: NCT01595191

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Bach music
Description: Infants listened to Bach or Mozart using the compact discs entitled Baby Bach and Baby Mozart (Baby smart, Nir Zvi, Israel).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mozart music
Description: Infants listened to Bach or Mozart using the compact discs entitled Baby Bach and Baby Mozart (Baby smart, Nir Zvi, Israel).
Study: NCT03897530

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smoking Cessation Intervention
Description: View and purchase hypothetical tobacco products during four distinctly different ETM

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Functional Assessment
Description: Visual attention is evaluated via eye-tracking equipment

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study: NCT04176120

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TTAX01
Description: TTAX01 is a cryopreserved human umbilical cord product derived from donated human placental tissue following healthy, live, caesarian section, full-term births after determination of donor eligibility and placenta suitability. TTAX01 is manufactured by TissueTech Inc. utilizing a proprietary CRYOTEK® process, which devitalizes the living cells but retains the natural structural and biological characteristics relevant to this tissue. TTAX01 is aseptically processed in compliance with current Good Tissue Practices (cGTP). TTAX01 will be manufactured in various sizes, stored in a medium of lactated Ringer's/glycerol (1:1).

Intervention type: OTHER
Group type: OTHER
Intervention: Standard Care
Description: Standard care is defined in this protocol to consist of the following:~* Debridement;~* Wound cleansing, using sterile saline, a non-ionic cleanser or a hypochlorous solution. Antiseptic agents including hydrogen peroxide, acetic acid, chlorhexidine, povidone/iodine, and cetrimide should not be used. Topical antimicrobials and silver dressings are also prohibited;~* Primary wound dressings including a non-adherent, standard foam pad with or without a hydrogel beneath the dressing, or and alginate dressing, as is appropriate to maintain a moist wound environment while managing exudate;~* A secondary retention bandage appropriate to the amount of wound exudate, so as to avoid maceration of the peri-wound skin;~* Off-loading device appropriate to the location of wound with full length boot or total contact cast (unless not appropriate where a substitute off-loading device can be made with sponsor approval); and,~* Appropriate use of systemic antibiotics.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard Care
Description: Standard care is defined in this protocol to consist of the following:~* Debridement;~* Wound cleansing, using sterile saline, a non-ionic cleanser or a hypochlorous solution. Antiseptic agents including hydrogen peroxide, acetic acid, chlorhexidine, povidone/iodine, and cetrimide should not be used. Topical antimicrobials and silver dressings are also prohibited;~* Primary wound dressings including a non-adherent, standard foam pad with or without a hydrogel beneath the dressing, or and alginate dressing, as is appropriate to maintain a moist wound environment while managing exudate;~* A secondary retention bandage appropriate to the amount of wound exudate, so as to avoid maceration of the peri-wound skin;~* Off-loading device appropriate to the location of wound with full length boot or total contact cast (unless not appropriate where a substitute off-loading device can be made with sponsor approval); and,~* Appropriate use of systemic antibiotics.
Study: NCT01186107

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endeavor Resolute stent
Description: zotarolimus-eluting stent

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cypher stent
Description: sirolimus-eluting stent
Study: NCT01179061

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apelin
Description: Cardiac index will be assess in patients through the 6hr infusion, using thoracic cardiac bioimpedance. Prior to starting the infusion there will be a 30 minute run in period to achieve a stable cardiac index. Thereafter the infusion will be started, with cardiac index assess every five minutes during the first hour. For each subsequent hour participants will be free to mobilise for the thirty minute periods, with cardiac index and systemic haemodynmics assess for the following thirty minutes.~Additionally during the first hour pulmonary artery pressure will be estimated from pulmonary artery pressures assessed with echocardiography. This will be assessed at baseline with four further measurements during the first hour of infusion.~Participants will be asked to void prior to the study starting, thereafter all urine will be collected during the course of the study. Relevant biochemical/humoral factors will be assessed in the urine.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: As per apelin arm, however we will use a saline placebo infusion. All other aspects will remain the same.
Study: NCT03545997

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Montelukast 10mg
Description: The capsules will be presented in box of 95 capsules packaged in unit blister

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Montelukast 10mg
Description: The capsules will be presented in box of 95 capsules packaged in unit blister

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Mannitol 350mg The capsules will be presented in box of 95 capsules packaged in unit blister

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Mannitol 350mg The capsules will be presented in box of 95 capsules packaged in unit blister
Study: NCT03560466

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dupilumab (SAR231893/REGN668)
Description: Pharmaceutical form: solution for injection~Route of administration: subcutaneous (sc)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asthma controller therapies (incl. prednisone/prednisolone)
Description: Pharmaceutical form: powder, or solution, or pill~Route of administration: inhaled, oral or parenteral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Asthma reliever therapies
Description: Pharmaceutical form: powder or solution~Route of administration: inhaled
Study: NCT03105648

Intervention type: OTHER
Intervention: computerized cytomorphometry
Description: use computer program to analyse the characteristics of thyroid cells obtained by fine needle aspiration cytology examination

Intervention type: OTHER
Intervention: computerized cytomorphometry
Description: use computer program to analyse the characteristics of thyroid cells obtained by fine needle aspiration cytology examination
Study: NCT00915655

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: darunavir
Description: Type=exact number, unit=mg, number=400, formulation=tablet, route=oral. 2 tablets of darunavir administered once daily for 48 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ritonavir
Description: Type=exact number, unit=mg, number=100, formulation=capsule, route=oral. 1 capsule of ritonavir administered once daily for 48 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: zidovudine
Description: NRTI (zidovudine) administered as per approved, marketed, or considered local standard of care for patients aged between 12 and \< 18 years in a particular country

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lamivudine
Description: NRTI (lamivudine) administered as per approved, marketed, or considered local standard of care for patients aged between 12 and \< 18 years in a particular country

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: abacavir
Description: NRTI (abacavir) administered as per approved, marketed, or considered local standard of care for patients aged between 12 and \< 18 years in a particular country
Study: NCT03986047

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Thermal care
Description: Wearing of a light elastic lower back heating wrap, which heats up to 40°C within 30 minutes and maintains this temperature continuously for 8 hours. Heat wrap will be worn during the day for 8 hours on 7 consecutive days.
Study: NCT02397421

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsules containing microcrystalline cellulose Ph Eur overencapsulated in a hard gelatine capsule shell to match the active comparator
Study: NCT02444260

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: Midazolam will administered intravenously. 1 mg given stat. Titrated by 1 mg to a maximum dose of 10 mg. Additional sedation will be given to achieve and maintain a score of 2-3 on the Ramsay sedation scale during the procedure, up to the maximum dose of 10mg.

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Intravenous Normal Saline
Description: Intravenous normal saline will be infused by non-blinded anaesthetist

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Bupivocaine
Description: Bupivcaine 0.25% solution administered by wound infiltration to a maximum dose of 2 mg/kg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivocaine
Description: Bupivcaine 0.25% solution administered by wound infiltration to a maximum dose of 2 mg/kg

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Lignocaine HCl
Description: Lignocaine !% solution administered by wound infiltration to a maximum dose of 4.5mg/kg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lignocaine HCl
Description: Lignocaine !% solution administered by wound infiltration to a maximum dose of 4.5mg/kg
Study: NCT01057420

Intervention type: DRUG
Group type: OTHER
Intervention: oxygen inhalation
Description: Inhalation of 80% oxygen via face mask
Study: NCT04249310

Intervention type: DRUG
Intervention: Tiotropium/Olodaterol
Description: Soft Mist Inhaler product

Intervention type: DRUG
Intervention: Tiotropium
Description: Soft Mist Inhaler product
Study: NCT03023969

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ozone oxygen mixture
Description: receive 10 ml of ozone oxygen mixture under variable dosing

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ozone oxygen mixture
Description: receive 10 ml of ozone oxygen mixture under variable dosing
Study: NCT00590447

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rituximab monotherapy
Description: 375 mg/m2, IV on days 1, 8, 15, 22, 50, 72, 94 and 116. In case of disease progression during the first 4 administration of rituximab antibody or the 4 weeks interval between course 4 and 5 the patients directly enter R-CHOP chemotherapy (Arm B).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sequential R-CHOP
Description: 375 mg/m2 rituximab, IV on days 1, 8, 15, 22, 50, 72, 94 and 116. Cyclophosphamid 750 mg/m2, adriamycine 50 mg/m2 and vincristine 1.4mg/m2, IV and prednisone 50mg/m2, PO every 3 weeks at days 50, 72, 94 and 116.~In case of disease progression during the first 4 administration of rituximab antibody or the 4 weeks interval between antibody and R-CHOP administration the patients directly enter R-CHOP chemotherapy.
Study: NCT03779464

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: S1 or Gemcitabine
Description: Gemcitabine 1000 mg/m² (D1, D8, q3w) and S-1 (40 mg BID for body surface area \< 1.25 m²; 50 mg BID for body surface area of 1.25-1.5 m²; and 60 mg BID for body surface area \>1.5 m²; D1-14, q3w)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S1 or Gemcitabine
Description: Gemcitabine 1000 mg/m² (D1, D8, q3w) and S-1 (40 mg BID for body surface area \< 1.25 m²; 50 mg BID for body surface area of 1.25-1.5 m²; and 60 mg BID for body surface area \>1.5 m²; D1-14, q3w)
Study: NCT02972554

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propanolol hydrochloride
Description: One-time dose of 40mg of propranolol

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Outside casing matching that of active drug
Study: NCT02322203

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Niacin Extended Release
Description: Subjects will receive a 2 week supply of the dietary supplement Rugby Extended Release Niacin (250 mg/tablet) Niacin and will be instructed to take 2 tablets per day (500 mg/day) for the first seven days and then increase to 4 tablets per day (1000 mg/day) during the following 7 days. Subjects will then be escalated to 2000 mg/day for 14 weeks.